Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Feb;31(2):207-12.
doi: 10.1002/hed.20949.

Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma

Andre A Konski  1 , Kathryn Winter, Bernard F Cole, Kie-Kian Ang, Karen K Fu
Affiliations
Clinical Trial

Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma

Andre A Konski et al. Head Neck. 2009 Feb.

Abstract

Background: To evaluate quality-adjusted survival (QAS) of patients with locally advanced squamous cell carcinoma of the head and neck treated with 4 different radiation fractionation schedules.

Methods: QAS was calculated using the quality-adjusted time without toxicity or relapse (Q-TWiST) methodology. Utilities (patient preferences for certain health states) were obtained by threshold analysis. Q-TWiST therefore equaled TWiST + ([weight for toxicity] x [time spent in toxicity]) + ([weight for relapse] x [time spent in relapse]).

Results: A statistically significant increase in QAS existed for patients treated with hyperfractionated radiotherapy compared with standard fractionated radiotherapy (SFX) with a toxicity utility > or = 0.57 and relapse utility < or = 0.72. No statistically significant difference was observed for patients treated with the other 2 fractionation schedules compared with SFX.

Conclusion: Q-TWiST analysis identified patient groups that would benefit from more aggressive therapy. Further investigation with patient-generated utilities is needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Standard Fractionation Radiotherapy (SFX) Partitioned Survival
Figure 2
Figure 2
Hyperfractionation Radiotherapy (HFX) Partitioned Survival
Figure 3
Figure 3
Accelerated Hyperfractionated Radiotherapy with Split (AHFXS) Partitioned Survival
Figure 4
Figure 4
Accelerated Fractionated Radiotherapy with Concomitant Boost (AFXC) Partitioned Survival
Figure 5
Figure 5. Hyperfractionated Radiotherapy (HFX) versus Standard Radiotherapy (SFX) Threshold Plot
This is a threshold analysis for determining utilities between Standard Radiotherapy (SFX) and Hyperfractionated Radiotherapy (HFX). Patients with a combination of utilities above the line would prefer HFX.
Figure 6
Figure 6. Accelerated Hyperfractionated Radiotherapy with Split versus Standard Fractionated Radiotherapy Threshold Plot
Threshold analysis comparing Accelerate Hyperfractionated radiotherapy with split (AHFXS) compared to standard radiotherapy (SFX). There is no combination of utilities that would result in AHFXS being superior to SFX.
Figure 7
Figure 7. Accelerated Fractionate Radiotherapy with Concomitant Boost versus Standard Fractionated Radiotherapy Threshold Plot
Threshold analysis comparing Accelerate Fractionated Radiotherapy with Concomitant boost (AFXC) compared to standard radiotherapy (SFX). There is no combination of utilities that would result in AFXC being superior to SFX.
See this image and copyright information in PMC

References

    1. Regine W, Scott C, Murray K, et al. Neurocognitive Outcome in Brain Metastasis Patients Treated with Accelerated Fractionation (AF) vs. Accelerated Hyperfractionation (AH) Whole Brain Radiotherapy (WBRT): An Analysis from Radiation Therapy Oncology Group (RT)G) Study 91-04. Int J Radiat Oncol Biol Phys. 2000;48:158–159. - PubMed
    1. Choucair A, Scott C, Urtasun R, et al. Quality of Life and Neuropsychological Evaluation for Patients with Malignant Astrocytomas. RTOG 91-14. Int J Radiat Oncol Biol Phys. 1997;38(1):9–20. - PubMed
    1. Johnson D, Scott C, Marks J, et al. Assessment of Quality of Life and Oral Function of Patients Participating in a Phase II Study of Radioprotection of Oral and Pharyngeal Mucosa by the Prostaglandin E1 Analoge Misoprostol (RTOG 96-07) Int J Radiat Oncol Biol Phys. 2001;51:97. - PubMed
    1. Scott C, Stern J, Asbell S, et al. Age and Marital Status Linked to Quality of Life of Long Term Survivors of Head and Neck or Prostate Cancer: Report from a Survey of Radiation Therapy Oncology Group Patients. Int J Radiat Oncol Biol Phys. 2001;51:98.
    1. Fisher J, Scott C, Fu K, et al. Treatment Patient and Tumor Characteristics Impact Quality of Life (QOL) in Patients with Locally Advanced Squamous Cell Cancer of The Head and Neck: Report of The Radiation Therapy Oncology Group (RTOG) Trial 90-03. Int J Radiat Oncol Biol Phys. 2001;51:98.

Publication types

MeSH terms